The Merck Index Online is an encyclopaedic database of chemical substances – an evolution of the printed reference work The Merck Index. While the content has a focus on chemicals and biologicals of ...

Ten Times to Try Telehealth from Trusted Medical Reference: MerckManuals.com RAHWAY, N.J., September 10, 2024 – Merck Manuals, an authoritative online medical reference, shares advice from experts on ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

From the late 1950s to early 1980s, for example, Merck medical scientist Dr. Maurice Hilleman, considered “the father of modern vaccines,” helped develop over 40 vaccines to protect human and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck operates in the medical sector and competes with big pharma companies like Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Co. (NYSE: BMY), and Eli Lilly and Co. (NYSE: LLY). Merck's top ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Awardees will receive a $1,500 stipend to cover ACS Fall Meeting expenses. They will present their research at a Women Chemists Committee (WCC)/Merck half-day symposium and be recognized at the Awards ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Merck broke down the results Friday at the European Society of Medical Oncology Congress in Barcelona. In an email, the company pointed out that the majority of patients in LITESPARK-005 received ...